Literature DB >> 7890639

Role of intron I in expression of the human factor IX gene.

S Kurachi1, Y Hitomi, M Furukawa, K Kurachi.   

Abstract

The first intron (intron I) of the human factor IX gene, which has been previously suggested of having an expression-augmenting activity, was systematically studied for its potential enhancer activity. When tested with the chloramphenicol acetyltransferase expression vector with a minimal factor IX promoter, subregions of intron I showed only marginal enhancing activities (1.7-1.9-fold enhancement at the highest). Smaller subregions encompassing nucleotides 5660-6350 of the intron sequence even showed some weak negative regulatory activities (approximately 50% suppression at the highest), while a cytomegalovirus enhancer sequence, which was used as the positive control, had a 7-fold enhancement. A set of three factor IX minigene expression vectors with the same factor IX promoter were then constructed: p-416FIXc which contained the factor IX cDNA, p-416FIXm1 which contained the factor IX cDNA with a largely truncated intron I, and p-416FIXm2 which contained the factor IX cDNA with the intron I sequence further truncated. The p-416FIXm1 and p-416FIXm2 constructs showed 7-9-fold higher expression activities than p-416FIXc. The elevated factor IX antigen levels agreed well with the grossly elevated factor IX clotting activity and mRNA levels. These results indicate that the expression enhancing activity of intron I is not due to specific enhancer elements present in the intron subsequences, but is due to functional splicing sequences present in the precursor mRNAs produced from the minigene constructs containing intron I. By being efficiently assembled into spliceosome complexes, transcripts with splicing sequences may be better protected in the nucleus from random degradations than those without such sequences.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890639     DOI: 10.1074/jbc.270.10.5276

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy.

Authors:  Sara Kathleen Powell; Ricardo Rivera-Soto; Steven James Gray
Journal:  Discov Med       Date:  2015-01       Impact factor: 2.970

3.  Bioengineering of differentiated hepatocytes with human factor IX-expressing plasmids in vitro.

Authors:  Azadeh Sadat Azadbakhsh; Mohammad Reza Sam; Farrah Farokhi
Journal:  Bioengineered       Date:  2016-07-26       Impact factor: 3.269

4.  Variables affecting in vivo performance of high-capacity adenovirus vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Biermann; Volker Dries; Stefan Kochanek
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.

Authors:  R W Herzog; J N Hagstrom; S H Kung; S J Tai; J M Wilson; K J Fisher; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  Tissue-preferential expression of a rice alpha-tubulin gene, OsTubA1, mediated by the first intron.

Authors:  J S Jeon; S Lee; K H Jung; S H Jun; C Kim; G An
Journal:  Plant Physiol       Date:  2000-07       Impact factor: 8.340

7.  Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.

Authors:  Denise E Sabatino; Amy M Lange; Ekaterina S Altynova; Rita Sarkar; Shangzhen Zhou; Elizabeth P Merricks; Helen G Franck; Timothy C Nichols; Valder R Arruda; Haig H Kazazian
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

8.  Assessing the potential for AAV vector genotoxicity in a murine model.

Authors:  Hojun Li; Nirav Malani; Shari R Hamilton; Alexander Schlachterman; Giulio Bussadori; Shyrie E Edmonson; Rachel Shah; Valder R Arruda; Federico Mingozzi; J Fraser Wright; Frederic D Bushman; Katherine A High
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

9.  Heterogeneous nuclear ribonucleoprotein A3 is the liver nuclear protein binding to age related increase element RNA of the factor IX gene.

Authors:  Toshiyuki Hamada; Sumiko Kurachi; Kotoku Kurachi
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

Review 10.  Advances in gene therapy for hemophilia: basis, current status, and future perspectives.

Authors:  Tsukasa Ohmori
Journal:  Int J Hematol       Date:  2018-08-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.